| PAR Stock | | | 290.40 11.35 4.07% |
Par Drugs financial indicator trend analysis is much more than just breaking down Par Drugs And prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Par Drugs And is a good investment. Please check the relationship between Par Drugs Other Operating Expenses and its Depreciation And Amortization accounts. Check out
Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
Other Operating Expenses vs Depreciation And Amortization
Other Operating Expenses vs Depreciation And Amortization Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Par Drugs And Other Operating Expenses account and
Depreciation And Amortization. At this time, the significance of the direction appears to have strong relationship.
The correlation between Par Drugs' Other Operating Expenses and Depreciation And Amortization is 0.67. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Depreciation And Amortization in the same time period over historical financial statements of Par Drugs And, assuming nothing else is changed. The correlation between historical values of Par Drugs' Other Operating Expenses and Depreciation And Amortization is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Par Drugs And are associated (or correlated) with its Depreciation And Amortization. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation And Amortization has no effect on the direction of Other Operating Expenses i.e., Par Drugs' Other Operating Expenses and Depreciation And Amortization go up and down completely randomly.
Correlation Coefficient | 0.67 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Par Drugs And. It is also known as Par Drugs overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.
Most indicators from Par Drugs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Par Drugs And current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
As of November 30, 2024,
Selling General Administrative is expected to decline to about 11.4
M. In addition to that,
Tax Provision is expected to decline to about 29.1
M | 2021 | 2022 | 2023 | 2024 (projected) |
Total Revenue | 742.0M | 951.0M | 956.4M | 669.2M | Depreciation And Amortization | 32.8M | 32.3M | 34.4M | 33.2M |
Par Drugs fundamental ratios Correlations
Click cells to compare fundamentals
Par Drugs Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Par Drugs fundamental ratios Accounts
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Par Stock
Balance Sheet is a snapshot of the
financial position of Par Drugs And at a specified time, usually calculated after every quarter, six months, or one year. Par Drugs Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Par Drugs and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Par currently owns. An asset can also be divided into two categories, current and non-current.